JP5502253B2 - 新規化合物 - Google Patents

新規化合物 Download PDF

Info

Publication number
JP5502253B2
JP5502253B2 JP2001562559A JP2001562559A JP5502253B2 JP 5502253 B2 JP5502253 B2 JP 5502253B2 JP 2001562559 A JP2001562559 A JP 2001562559A JP 2001562559 A JP2001562559 A JP 2001562559A JP 5502253 B2 JP5502253 B2 JP 5502253B2
Authority
JP
Japan
Prior art keywords
seq
polypeptide
sequence
polynucleotide
identity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001562559A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003530088A (ja
JP2003530088A5 (enExample
Inventor
カーブゾン−シルヴァ，テレサ，エリザ，ヴァージニア
キャサルト，ジーン−ポール
コーヘ，ティエリー
ガウリス，スワン，ローマン，ジーン−トーマス
ワイ デ バソルス，カルロタ ヴィナルス
Original Assignee
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0004269A external-priority patent/GB0004269D0/en
Priority claimed from GB0009905A external-priority patent/GB0009905D0/en
Priority claimed from GB0021080A external-priority patent/GB0021080D0/en
Application filed by グラクソスミスクライン バイオロジカルズ ソシエテ アノニム filed Critical グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Publication of JP2003530088A publication Critical patent/JP2003530088A/ja
Publication of JP2003530088A5 publication Critical patent/JP2003530088A5/ja
Application granted granted Critical
Publication of JP5502253B2 publication Critical patent/JP5502253B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2001562559A 2000-02-23 2001-02-16 新規化合物 Expired - Fee Related JP5502253B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0004269A GB0004269D0 (en) 2000-02-23 2000-02-23 Novel compounds
GB0004269.7 2000-02-23
GB0009905.1 2000-04-20
GB0009905A GB0009905D0 (en) 2000-04-20 2000-04-20 Novel compounds
GB0021080A GB0021080D0 (en) 2000-08-25 2000-08-25 Novel compounds
GB0021080.7 2000-08-25
PCT/EP2001/001779 WO2001062778A2 (en) 2000-02-23 2001-02-16 Tumour-specific animal proteins

Publications (3)

Publication Number Publication Date
JP2003530088A JP2003530088A (ja) 2003-10-14
JP2003530088A5 JP2003530088A5 (enExample) 2008-03-27
JP5502253B2 true JP5502253B2 (ja) 2014-05-28

Family

ID=27255552

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001562559A Expired - Fee Related JP5502253B2 (ja) 2000-02-23 2001-02-16 新規化合物

Country Status (23)

Country Link
US (5) US20030157118A1 (enExample)
EP (2) EP1265915B1 (enExample)
JP (1) JP5502253B2 (enExample)
KR (3) KR100848973B1 (enExample)
CN (1) CN1254541C (enExample)
AT (1) ATE487733T1 (enExample)
AU (3) AU2001256156B2 (enExample)
BR (1) BR0108654A (enExample)
CA (1) CA2400842C (enExample)
CY (2) CY1111156T1 (enExample)
CZ (1) CZ303468B6 (enExample)
DE (1) DE60143425D1 (enExample)
DK (2) DK1265915T3 (enExample)
ES (1) ES2389445T3 (enExample)
HU (1) HUP0300054A3 (enExample)
IL (2) IL151097A0 (enExample)
MX (1) MXPA02008279A (enExample)
NO (1) NO332141B1 (enExample)
NZ (1) NZ520673A (enExample)
PL (1) PL209127B1 (enExample)
PT (2) PT1265915E (enExample)
SI (2) SI1265915T1 (enExample)
WO (1) WO2001062778A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL209127B1 (pl) * 2000-02-23 2011-07-29 Smithkline Beecham Biolog Środek farmaceutyczny do stosowania w immunoterapeutycznym leczeniu raka i sposób diagnozowania u pacjenta obecności lub podatności na raka
PT1889630E (pt) * 2000-10-18 2012-02-29 Glaxosmithkline Biolog Sa Vacinas compreendendo o antigénio mage ligado a um fragmento da proteína d
US8039602B2 (en) 2000-10-31 2011-10-18 Ryogen Llc Isolated genomic polynucleotide fragments from the p15 region of chromosome 11
GB0100756D0 (en) 2001-01-11 2001-02-21 Powderject Res Ltd Needleless syringe
GB0111974D0 (en) * 2001-05-16 2001-07-04 Glaxosmithkline Biolog Sa Novel Compounds
EP1575515A4 (en) * 2002-08-29 2007-08-08 Genentech Inc ACHAETE-SCUTE-SIMILAR 2 POLYPEPTIDES AND CODING NUCLEIC ACIDS AND METHOD FOR THE DIAGNOSIS AND TREATMENT OF A TUMOR
CN1310033C (zh) * 2004-03-23 2007-04-11 中国医学科学院肿瘤医院肿瘤研究所 一种检测血清蛋白指纹的新方法
EP2390367A1 (en) 2006-06-02 2011-11-30 GlaxoSmithKline Biologicals s.a. Methods for identifying whether a patient will be responder or not to immunotherapy based on the differential expression of the UBD gene
GB0708758D0 (en) 2007-05-04 2007-06-13 Powderject Res Ltd Particle cassettes and process thereof
UY31101A1 (es) 2007-05-24 2009-01-05 Glaxosmithkline Biologicals Sa Composición antigénica liofilizada
US8916514B2 (en) * 2009-05-27 2014-12-23 Glaxosmithkline Biologicals, S.A. CASB7439 constructs
GB0917457D0 (en) 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
WO2011066505A2 (en) * 2009-11-30 2011-06-03 Pathak Holdings Llc Methods and compositions for filling fleshy fruits and vegetables
DK3311827T3 (da) * 2011-10-03 2023-04-03 Canqura Oncology Ab Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærere for amfipatiske eller hydrofobe molekyler inden for det medicinske område, inklusiv cancerbehandling, samt fødevarerelaterede forbindelser
WO2016146143A1 (en) 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
GB201520592D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
CA3010779A1 (en) 2016-03-16 2017-09-21 Amal Therapeutics Sa Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine
DK3515476T3 (da) 2016-09-21 2024-09-02 Amal Therapeutics Sa Fusion der omfatter et cellepenetrerende peptid, en multiepitop og en trl-peptidagnost til behandlingen af cancer
US10422675B2 (en) 2017-06-09 2019-09-24 Aps Technology, Inc. System and method for monitoring mud flow in a component of drilling system

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
DE10399032I1 (de) 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
WO1990013361A1 (en) 1989-05-04 1990-11-15 Southern Research Institute Improved encapsulation process and products therefrom
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
WO1991002805A2 (en) 1989-08-18 1991-03-07 Viagene, Inc. Recombinant retroviruses delivering vector constructs to target cells
KR920007887B1 (ko) 1989-08-29 1992-09-18 스즈키 지도오샤 고오교오 가부시키가이샤 내연기관의 배기가스 정화장치
NZ235315A (en) 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
ES2113371T3 (es) 1989-11-16 1998-05-01 Univ Duke Transformacion de celulas epidermicas de tejidos animales con la ayuda de particulas.
FR2658432B1 (fr) 1990-02-22 1994-07-01 Medgenix Group Sa Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation.
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
WO1992001070A1 (en) 1990-07-09 1992-01-23 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce High efficiency packaging of mutant adeno-associated virus using amber suppressions
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
GB9022190D0 (en) 1990-10-12 1990-11-28 Perham Richard N Immunogenic material
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
ES2197145T3 (es) 1991-08-20 2004-01-01 The Government Of The Usa As Represented By The Secretary Of The Deptm. Of Health And Human Services Transferencia de genes mediada por adenovirus al gastrointestinal.
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
WO1993015763A1 (en) * 1992-02-18 1993-08-19 Smithkline Beecham Corporation Vaccinal polypeptides
WO1993023011A1 (en) 1992-05-18 1993-11-25 Minnesota Mining And Manufacturing Company Transmucosal drug delivery device
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
ATE180407T1 (de) 1993-01-11 1999-06-15 Dana Farber Cancer Inst Inc Induktion der antworten zytotoxischer t- lymphozyten
US5654186A (en) 1993-02-26 1997-08-05 The Picower Institute For Medical Research Blood-borne mesenchymal cells
FR2702160B1 (fr) 1993-03-02 1995-06-02 Biovecteurs As Vecteurs particulaires synthétiques et procédé de préparation.
EP0693084A4 (en) 1993-04-06 1999-06-02 Hutchinson Fred Cancer Res CHIMERAL CYTOKINE RECEPTORS IN LYMPHOCYTE
FR2704145B1 (fr) 1993-04-21 1995-07-21 Pasteur Institut Vecteur particulaire et composition pharmaceutique le contenant.
CA2164623A1 (en) 1993-06-07 1994-12-22 Robert Enrico Pacifici Hybrid receptor molecules
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
AU8116494A (en) 1993-11-12 1995-06-13 Kenichi Matsubara Gene signature
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
DE69529495T2 (de) 1994-01-21 2003-06-12 Powderject Vaccines, Inc. Gasbetätigtes element zum austragen von genmaterial
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
EP1167378B1 (en) 1994-07-15 2011-05-11 University of Iowa Research Foundation Immunomodulatory oligonucleotides
FR2723849B1 (fr) 1994-08-31 1997-04-11 Biovector Therapeutics Sa Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
GB9502879D0 (en) 1995-02-14 1995-04-05 Oxford Biosciences Ltd Particle delivery
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
WO1997024447A1 (en) 1996-01-02 1997-07-10 Chiron Corporation Immunostimulation mediated by gene-modified dendritic cells
NZ331164A (en) * 1996-02-09 2000-02-28 Univ Liege Vaccines against varicella zoster virus gene 63 product
US5776683A (en) 1996-07-11 1998-07-07 California Pacific Medical Center Methods for identifying genes amplified in cancer cells
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US5811407A (en) 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US6355257B1 (en) 1997-05-08 2002-03-12 Corixa Corporation Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
DE69943359D1 (de) * 1998-02-05 2011-05-26 Glaxosmithkline Biolog Sa Tumorassoziierte Antigenderivate der Mage-Familie, zur Herstellung von Fusionsproteinen mit T-Helper Epitope und Zusammensetzungen zur Impfung
CA2320488C (en) 1998-02-12 2007-03-06 Immune Complex, Corporation Strategically modified hepatitis b core proteins and their derivatives
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
HUP0101047A3 (en) 1998-03-09 2004-10-28 Smithkline Beecham Biolog Combined vaccine compositions
TR200002930T2 (tr) 1998-04-09 2000-12-21 Smithkline Beecham Biologicals S.A. Kolaylaştırıcı kompozisyonlar
DK1104306T3 (da) 1998-08-10 2006-05-22 Antigenics Inc Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf
US6087168A (en) * 1999-01-20 2000-07-11 Cedars Sinai Medical Center Conversion of non-neuronal cells into neurons: transdifferentiation of epidermal cells
DE60031383T2 (de) * 1999-03-11 2007-11-15 Glaxosmithkline Biologicals S.A. Verwendung von casb618 polynucleotide und polypeptide
AU5788900A (en) 1999-07-07 2001-01-22 Tularik Inc. Diagnosis of cancer by detecting ash2 polypeptides or polynucleotides
AU2001236589A1 (en) 2000-02-04 2001-08-14 Aeomica, Inc. Methods and apparatus for high-throughput detection and characterization of alternatively spliced genes
PL209127B1 (pl) * 2000-02-23 2011-07-29 Smithkline Beecham Biolog Środek farmaceutyczny do stosowania w immunoterapeutycznym leczeniu raka i sposób diagnozowania u pacjenta obecności lub podatności na raka
US7811574B2 (en) * 2000-02-23 2010-10-12 Glaxosmithkline Biologicals S.A. Tumour-specific animal proteins
US8039602B2 (en) * 2000-10-31 2011-10-18 Ryogen Llc Isolated genomic polynucleotide fragments from the p15 region of chromosome 11
EP1575515A4 (en) 2002-08-29 2007-08-08 Genentech Inc ACHAETE-SCUTE-SIMILAR 2 POLYPEPTIDES AND CODING NUCLEIC ACIDS AND METHOD FOR THE DIAGNOSIS AND TREATMENT OF A TUMOR
US8916514B2 (en) 2009-05-27 2014-12-23 Glaxosmithkline Biologicals, S.A. CASB7439 constructs

Also Published As

Publication number Publication date
DK1265915T3 (da) 2011-02-14
CY1113109T1 (el) 2016-04-13
NO20024002L (no) 2002-10-22
US20030157118A1 (en) 2003-08-21
PL209127B1 (pl) 2011-07-29
AU5615601A (en) 2001-09-03
US8207123B2 (en) 2012-06-26
PT1650221E (pt) 2012-09-05
CN1426421A (zh) 2003-06-25
PL362698A1 (en) 2004-11-02
CA2400842C (en) 2013-01-15
DK1650221T3 (da) 2012-09-03
WO2001062778A3 (en) 2002-04-04
HUP0300054A3 (en) 2012-09-28
KR100848973B1 (ko) 2008-07-30
SI1265915T1 (sl) 2011-02-28
US20120244175A1 (en) 2012-09-27
ES2389445T3 (es) 2012-10-26
CY1111156T1 (el) 2015-06-11
NO332141B1 (no) 2012-07-02
NO20024002D0 (no) 2002-08-22
EP1650221A3 (en) 2006-12-20
EP1265915B1 (en) 2010-11-10
WO2001062778A2 (en) 2001-08-30
KR20080029007A (ko) 2008-04-02
JP2003530088A (ja) 2003-10-14
US20100291121A1 (en) 2010-11-18
US8535690B2 (en) 2013-09-17
CZ303468B6 (cs) 2012-10-03
AU2001256156B2 (en) 2006-01-05
EP1650221B1 (en) 2012-06-27
KR20090085697A (ko) 2009-08-07
HUP0300054A1 (hu) 2003-05-28
AU2006201042A1 (en) 2006-03-30
AU2006201042B2 (en) 2009-10-08
IL151097A0 (en) 2003-04-10
CA2400842A1 (en) 2001-08-30
MXPA02008279A (es) 2002-11-29
KR100919916B1 (ko) 2009-10-07
PT1265915E (pt) 2011-02-07
NZ520673A (en) 2004-09-24
EP1265915A2 (en) 2002-12-18
ATE487733T1 (de) 2010-11-15
EP1650221A2 (en) 2006-04-26
CZ20022874A3 (cs) 2003-02-12
KR20020079887A (ko) 2002-10-19
HK1093513A1 (en) 2007-03-02
SI1650221T1 (sl) 2012-09-28
BR0108654A (pt) 2003-04-29
US20110052615A1 (en) 2011-03-03
HK1052710A1 (en) 2003-09-26
CN1254541C (zh) 2006-05-03
IL151097A (en) 2012-05-31
US20060171953A1 (en) 2006-08-03
US7803379B2 (en) 2010-09-28
DE60143425D1 (de) 2010-12-23

Similar Documents

Publication Publication Date Title
US8535690B2 (en) Tumor specific animal proteins
AU2001256156A1 (en) Novel compounds
WO2002066506A2 (en) Use of casb7439 (ash2) in the immunotherapy of breast cancer
WO2002050103A2 (en) Tumour-related antigens
WO2002006338A1 (en) Vaccine comprising a lung tumour associated antigen
US7811574B2 (en) Tumour-specific animal proteins
WO2001034794A1 (en) Casb7434, an antigen over-expressed in colon cancer
EP1232258A1 (en) Colon tumour-associated antigens
EP1222198A2 (en) Human tumor-associated lak-4p related polynucleotides and polypeptides and their uses
WO2001057077A1 (en) Proteins that are specifically expressed or highly overexpressed in tumors and nucleic acids encoding them
WO2001080879A2 (en) Colorectal cancer vaccines and diagnosis
WO2002092627A2 (en) Use of casb 7439 for treatment and diagnosis of lung cancer
ZA200206746B (en) Tumour-specific animal proteins.
HK1052710B (en) Novel compounds
WO2003016344A2 (en) Use of lung carcinoma antigen
WO2002098913A2 (en) Polypeptides and corresponding polynucleotides for prophylaxis and treatment of colon cancer
WO2001034795A2 (en) Casb7435 polypeptide, nucleic acid encoding it, and their uses in treatment and diagnosis

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101221

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120113

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120123

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20120309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140212

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140313

R150 Certificate of patent or registration of utility model

Ref document number: 5502253

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees